Skip to content

A Study on the Pathogenesis and Determinants of Intravenous Leiomyomatosis

A Study on the Pathogenesis and Determinants of Intravenous Leiomyomatosis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06773819
Enrollment
30
Registered
2025-01-14
Start date
2025-05-01
Completion date
2027-12-31
Last updated
2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Infection, Intravenous Leiomyomatosis

Keywords

Intravenous leiomyomatosis, HPV

Brief summary

The goal of this observational study is to learn about the impact of HPV infection in women with intravenous leiomyomatosis(IVL). The main question it aims to answer is: Does HPV infection promote the development of IVL from uterine leiomyoma? Surgical sections and HPV-DNA test results will be collected in participants diagnosed with IVL or uterine leiomyoma.

Detailed description

Previous proteomic studies have demonstrated that HPV infection-related proteins are more highly expressed in intravenous leiomyomatosis (IVL) compared to uterine leiomyoma (uML). Consequently, we conducted a case-control study to investigate the association between HPV and the development of IVL. We recruited adult patients diagnosed with either IVL or uML, collected their medical histories, surgical specimens from various sites, and HPV-DNA test results from cervical exfoliated cells, and performed subsequent statistical analyses and mechanistic investigations.

Interventions

None listed

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* Adult female patients with suspected IVL or uterine leiomyoma who receive surgery at PUMCH * Be able to understand and sign the informed consent

Exclusion criteria

* Patients with other concurrent malignant tumors * Pregnant or lactating female * Postoperative pathology do not include IVL or uterine leiomyoma

Design outcomes

Primary

MeasureTime frame
HPV-DNA test resultFrom date of enrollment until the date of surgery at PUMCH or date of death from any cause, whichever came first, assessed up to 100 months

Contacts

Primary ContactBao Liu, MD
liubao72@aliyun.com010-69152592

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026